The genome is organized via CTCF-cohesin-binding sites, which partition chromosomes into 1-5 megabase (Mb) topologically associated domains (TADs), and further into smaller sub-domains (sub-TADs). Here we examined in vivo an ∼80 kb sub-TAD, containing the mouse α-globin gene cluster, lying within a ∼1 Mb TAD. We find that the sub-TAD is flanked by predominantly convergent CTCF-cohesin sites that are ubiquitously bound by CTCF but only interact during erythropoiesis, defining a self-interacting erythroid compartment. Whereas the α-globin regulatory elements normally act solely on promoters downstream of the enhancers, removal of a conserved upstream CTCF-cohesin boundary extends the sub-TAD to adjacent upstream CTCF-cohesin-binding sites. The α-globin enhancers now interact with the flanking chromatin, upregulating expression of genes within this extended sub-TAD. Rather than acting solely as a barrier to chromatin modification, CTCF-cohesin boundaries in this sub-TAD delimit the region of chromatin to which enhancers have access and within which they interact with receptive promoters.
. These elements appear to organize chromosomes into a series of increasingly complex topological structures (chromosome loops, subTADs, TADs and so on) 3 . However, not all CTCF-cohesin sites appear equivalent, and a variety of different functions have been attributed to such elements in different contexts, including: acting as boundaries to chromatin modifications [4] [5] [6] , facilitating interactions between regulatory elements 7, 8 , and insulating genes from tissue-specific enhancers [9] [10] [11] . However, at present, how they interact with each other and with other regulatory elements in their natural chromosomal context is poorly understood. To address this, we have examined the interactions between CTCF-cohesin sites, enhancers and promoters, and determined their functional role(s) using chromosome engineering of an ∼80 kb sub-TAD containing the well-characterized mouse α-globin cluster, in its natural chromosomal environment, in vivo. We find that CTCF-cohesin sites in this sub-TAD play a key role in regulating gene expression by delimiting the region of chromatin within which active enhancers can interact with receptive promoters.
Changes in chromatin and gene expression across the 1 Mb TAD containing the α-globin locus in erythroid cells The mouse α-globin cluster is located in close proximity to a cluster of 10 widely expressed genes near the boundary of a ∼1 Mb TAD as previously defined 12 ( Fig. 1a) . We have previously characterized the chromatin in and around the α-globin cluster and noted that activation of α-globin expression in erythroid cells is associated with the appearance of a broad domain of histone acetylation and modification by H3K4me1 spanning ∼80 kb including the α-globin genes and their regulatory elements (Fig. 1b) 13, 14 . Using assays for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq), DNase I hypersensitive sites sequencing (DNaseseq) and chromatin immunoprecipitation with high-throughput DNA sequencing (ChIP-seq), we have identified all promoters and enhancers in this region via their characteristic chromatin signatures (Fig. 1b) . We have shown that the α-globin genes are regulated by four The α-globin locus with enhancer elements (R1, R2, R3, Rm, and R4), gene promoters and CTCF binding sites marked by peaks of open chromatin as indicated by ATAC-seq tracks (reads per kilobase per million mapped reads (RPKM)) in mouse ES and primary erythroid cells. θ1 and θ2 refer to CTCF binding sites at the promoters of the θ-globin pseudogenes. All normalized ChIP-seq read densities (RPKM) represent an average of 2 independent experiments, in which 2 animals (erythroid cells) or 2 biologically independent samples (ES cells) were analysed in total, except for ES and erythroid H3K4me1, which represent single experiments. CTCF binding orientation is annotated with forward (red arrows) and reverse (blue arrows). Dashed boxes indicate clusters of convergent CTCF binding sites. Gene annotation is Refseq. The following data sets were previously published: ES SMC1 and SMC3 31 ; erythroid H3K4me3 14 ; ES CTCF, H3K27me3 and H3K4me1 38 ; ES H3K4me3 39 ; ES ATAC-seq 40 . (c) Relative gene expression of mouse primary erythroid versus ES cells measured by real-time qPCR and representing n = 3 independent experiment in which animals (erythroid cells) or n = 3 biologically independent samples (ES cells) were analysed in total. Bars represent the mean and the error bars represent the standard deviation (s.d.). Grey dots represent individual data points. P values are obtained via an unpaired, two-tailed Student's ttest. Not significant (NS), P > 0.05; * * * P < 0.001; * * * * P < 0.0001. (d) DNaseI footprints of HS-38 and HS-39 CTCF binding sites. CTCF motifs are indicated by arrows; red arrow: forward core motif, blue arrow: reverse core motif, and green arrow: upstream motif. P values indicate the significance of the match of the HS-38 and HS-39 sequence to the core consensus motif (derived with the FIMO tool as described previously 41 ). The DNaseI data were previously published 42 .
conserved erythroid-specific enhancers (R1-R4) and a mouse-specific element (Rm) located 14-38 kb upstream of the promoters [15] [16] [17] . Four of these enhancers (R1, R2, R3 and Rm) lie within the introns of an adjacent widely expressed gene (Nprl3) 15 . We show here that the remaining regions of open chromatin within and around the gene cluster, identified in all cell types analysed, correspond to binding sites for CTCF-cohesin (Fig. 1b) .
The α-globin genes and the closely linked, widely expressed gene (Nprl3), which lie together within the H3K4me1-marked domain, are expressed at high levels in erythroid cells (Fig. 1c) . Surrounding genes within the larger (1 Mb) TAD are unaffected by activation of the strong erythroid-specific enhancers and we show here that one of these genes (Rhbdf1) is marked by high levels of the Polycomb-mediated repressive mark (H3K27me3) and completely silenced in erythroid cells (Fig. 1b,c) . In this way, we have accounted for all regions of open chromatin, the corresponding regulatory elements, and the pattern of gene expression within and surrounding the α-globin locus.
An α-globin sub-TAD is surrounded by convergent CTCF-cohesin-binding sites that interact with each other specifically in erythroid cells
While the role of CTCF-cohesin-binding sites at boundaries between TADs are starting to be established 12 , less is known about the CTCFcohesin sites that are dispersed within TADs. These CTCF-cohesin sites are thought to contribute to the formation of smaller selfinteracting domains that have been termed sub-TADs 18 , contact domains 19 and insulated neighbourhoods 11, 20 . In contrast to TADs, sub-TADs (40 kb to 3 Mb, median size of 185 kb (ref. 19) ) often appear in a cell-specific manner and, as in the case of the 80 kb sub-TAD corresponding to the H3K4me1 and histone acetylationmarked α-globin domain, may be identified via an increased density of chromatin interactions (as seen by Capture-C, Fig. 2a ) and specific histone modifications in a specific cell type. Of interest, recent studies have shown a strong preference for interactions to occur between CTCF sites lying in a convergent orientation with respect to each other [21] [22] [23] [24] . We therefore established the orientation of CTCF binding sites surrounding and within the α-globin sub-TAD (Fig. 1b) . Motif orientations were predicted by inspecting each CTCF consensus core and flanking motifs and subsequently validated by analysing the directionality of associated DNaseI footprints in vivo ( Fig. 1d and Supplementary Fig. 1 ). This analysis revealed a striking pattern of CTCF orientations in which the regions flanking the α-globin genes and their enhancers were shown to contain clusters of largely convergently oriented CTCF binding sites (Fig. 1b) .
To investigate the mechanisms by which CTCF-cohesin-mediated domains may form, interact and influence the activity of strong tissuespecific enhancers and promoters, we performed next-generation Capture-C in mouse erythroid and non-erythroid, embryonic stem (ES) cells 17, 25 . In ES cells, α-globin is not expressed whereas transcription of flanking genes (Snrnp25, Mpg, Rhbdf1 and Nprl3) occurs in the absence of the erythroid-specific enhancer activity (Fig. 1b,c) . Using viewpoints from the enhancer region (R1) and the α-globin promoters (α1 and α2), in ES cells we observed broad, diffuse interactions extending across the entire gene cluster (Fig. 2a) . By contrast, in erythroid cells, we observed much stronger interactions throughout the sub-TAD but especially between the enhancers and promoters (Fig. 2a) .
Interaction profiles from nearby viewpoints located at the CTCFcohesin-binding sites directly flanking the α-globin cluster were very different. Despite their proximity to the α-globin enhancer elements, these sites clearly do not interact with the enhancers within the sub-TAD: rather, they interact with the domains of chromatin containing convergent CTCF-cohesin sites extending from the θ-globin promoters to the 3 flanks of the α-globin sub-TAD (Fig. 2b) . Of particular interest, despite the near-identical CTCF-cohesin binding landscape across the α-globin sub-TAD in erythroid and non-erythroid cells (Fig. 1b) , we observed significantly increased interactions between flanking CTCF-cohesin clusters in erythroid cells, suggesting the development of a hairpin-like structure of the sub-TAD in erythroid cells. While this proposed structure would exclude interactions between flanking sequences and α-globin enhancers, it would not prevent interactions between the two CTCF sites directly adjacent to the enhancers (HS-38 and HS-39) and the α-globin promoters. Such interactions may occur with the CTCF binding sites at the θ-globin promoters. Profiles from viewpoints located at the promoters of flanking genes (Mpg and Rhbdf1) are consistent with this topological model (Fig. 2c) , and suggest that CTCF-mediated chromatin interactions between domains flanking the α-globin cluster may insulate promoters contained within these regions from the activity of the α-globin enhancers by constraining their interactions with these strong enhancers. Consistent with this model, the Nprl3 gene, whose promoter is located within the α-globin sub-TAD, shows a sixfold increase in expression in erythroid cells compared with non-erythroid cells, whereas the expression of Mpg and Rhbdf1 lying outside the sub-TAD is unchanged and repressed in erythroid cells respectively (Fig. 1c) .
Deletion of CTCF-cohesin sites alters multiple chromatin interactions within the α-globin sub-TAD Close inspection of the chromatin profile identified two prominent CTCF-cohesin-binding sites (HS-38 and HS-39) and a less prominent site (HS-29) lying close to and directly upstream of the α-globin enhancers at the boundary of the erythroid-specific sub-TAD defined by histone acetylation and H3K4me1 enrichment. These CTCFcohesin sites are positioned in between the erythroid enhancers and the widely expressed upstream genes (Mpg, Rhbdf1 and Snrnp25), suggesting that they may act individually or together as an insulator, shielding these upstream genes from enhancer activity. To test this hypothesis in vivo, we used TALEN 26 and CRISPRmediated mutagenesis 27 to generate mice with small deletions in the binding sequences of these three CTCF-cohesin sites, singly and in combination ( Fig. 3 and Supplementary Fig. 2 ).
We first analysed erythroid cells of a mouse lacking both HS-38 and HS-39 (D3839). Mutation of the two CTCF core sequences resulted in a complete loss of CTCF binding at these sites (Figs 3, 4a and 5a), but in contrast to previous reports 28, 29 did not affect binding of CTCF to other, nearby sites. To investigate whether mutation of both HS-38 and HS-39 altered interactions between the regions of chromatin flanking the sub-TAD, we used the downstream CTCF binding site (HS48) as a Capture-C viewpoint. Although interactions between flanking domains remain intact in the D3839 mutant, the upstream boundary of the domain in erythroid cells shifts from the deleted HS-38/-39 sites to the next adjacent upstream site (HS-59) site within the Rhbdf1 gene (Fig. 4a) . Capture-C using the R1 enhancer as a viewpoint shows that, while interactions between R1 and the α-globin promoters appear to be unchanged, ablation of CTCF binding in the D3839 mutant results in increased interactions between R1 and a region of chromatin, directly upstream, containing the Mpg, Rhbdf1 and Snrnp25 genes (Fig. 4b) . This is further confirmed by the interaction profiles obtained from the Rhbdf1 and Mpg promoters that show a strong increase of interactions with the R1 and R2 enhancers and the α-globin genes, while losing interactions with the downstream genomic region flanking the cluster (Fig. 4c) . Thus, the elimination of CTCF binding in the D3839 mutant is associated with an entirely new set of contacts between the α-globin enhancers and the Rhbdf1 and Mpg genes. Importantly, these interactions occur with non-erythroid promoters and involve interactions with promoters located upstream, in the opposite direction to those normally seen from the α-globin enhancers. In the proposed hairpin analogy of the sub-TAD, contacts within the CTCF-cohesin stem of the hairpin have shifted to increase the region of chromatin within its loop that now includes the Mpg, Rhbdf1 and Snrnp25 genes.
Mutation of CTCF-cohesin sites alters gene expression in the α-globin sub-TAD To examine whether the changes in local topology caused by the deletion of CTCF binding sites influence transcription in erythroid cells, we performed RNA sequencing (RNA-seq) on D3839 and wildtype primary erythroid cells. We found that expression of the three genes whose promoters are located in the genomic region that shows increased interactions with the R1 enhancer (Fig. 4b) , Mpg, Rhbdf1 and Snrnp25, is strongly upregulated in D3839 mutant mice (Fig. 5a-c) .
Housekeeping genes Mpg and Snrnp25 are normally expressed in wild-type erythroid cells but in the absence of HS-38 and HS-39 their expression increases by 12-and 6-fold, respectively. Interestingly, the Rhbdf1 gene, which is normally silenced by Polycomb group complexes in wild-type erythroid cells, increases its expression ∼600-fold in the D3839 mutant. In ES cells, Rhbdf1 is transcribed at relatively high levels. Even when compared with this active gene regulatory state, expression was significantly increased under the influence of the α-globin enhancers in the absence of CTCF insulation in D3839 erythroid cells (Fig. 5c ). By contrast, the Il9r gene, whose promoter is located within the chromatin region in which interactions between flanking CTCF-cohesin domains are retained in the D3839 mutant ( Fig. 4a ), remained inactive ( Fig. 5b) and insulated from the influence of the α-globin enhancers. We also detected no significant changes in expression of the α-or θ-globin genes (Fig. 5c) , consistent with the identical interaction profile of the R1 enhancer with the α-like globin promoters in D3839 mutant mice (Fig. 4 ) and the lack of any detectable change in the haematological phenotype (Fig. 5d ).
Not all CTCF sites in the sub-TAD are equivalent
Clearly, mutation of both HS-38 and HS-39 sites causes a change in the functional interactions between the α-globin enhancers and the promoters of the surrounding genes in the TAD. It has been suggested that effective chromatin boundaries are formed by two directly adjacent divergent CTCF binding sites 30 . Therefore, we next made and analysed mice with single deletions of CTCF binding at either the HS-38 (D38) or HS-39 (D39) elements ( Supplementary Fig. 2 ). Loss of HS-38 alone led to an upregulation of the upstream Mpg, Rhbdf1 and Snrnp25 genes, although to a lesser extent than that observed in the D3839 mice (Fig. 5e ). Rhbdf1 was tenfold less upregulated in the D38 mutant than in the double D3839 mutant, suggesting that the presence of HS-39 in the D38 mutant prevents a complete loss of enhancer insulation. However, deletion of HS-39 alone did not have a strong effect on local gene expression (Fig. 5e ). The observation that loss of HS-39 does not result in gene expression changes is consistent with the fact that only HS-38 is conserved across mammals including human and bound by higher levels of CTCF-cohesin, suggesting this site is sufficient for adequate enhancer insulation. These data do not exclude the opposite orientation of HS-38 and HS-39 or the difference in the composition of their CTCF binding motif as possible causes for this difference in insulator activity ( Supplementary Fig. 1 ). Finally, we generated a mouse lacking the HS-29 CTCF binding site (D29), located between the R1 and R2 enhancers. While the loss of CTCF binding at HS-29 resulted in increased interactions between the enhancers and the α-globin promoters ( Supplementary Fig. 3 ), these changes did not result in any detectable changes in local gene expression or histone modifications ( Fig. 5f and Supplementary Fig. 4 ). However, minor changes in α-globin gene expression may not have been detected by quantitative PCR (qPCR), which cannot detect fractional changes in expression. Notably, the HS-29 CTCF site binds lower levels of CTCF and cohesin than HS-38, possibly providing an explanation for its lack of boundary activity.
The CTCF-cohesin boundary constrains enhancer interactions rather than encroachment of chromatin modifications
Our results demonstrate that the removal of a bona fide insulator lying within a TAD does not simply cause encroachment of one chromatin state into another, but rather extends the range of interactions from a strong enhancer to flanking promoters. This suggests that enhancerpromoter interactions may be promiscuous rather than specific and that such interactions are normally constrained, in some way, by CTCF-cohesin-binding sites. In this respect, it was of interest that the normally silent Rhbdf1 promoter acquired high levels of H3K4me3 in D3839 erythroid cells, consistent with its ectopic expression in these mutant cells (Fig. 6a,b) . Similar increases in H3K4me3 were also noted at the Mpg promoter, and, to a lesser extent, at the Snrnp25 promoter, consistent with their transcriptional upregulation in D3839 erythroid cells. Following the smaller effects on gene transcription, the single disruption of HS-38 CTCF binding resulted in the recruitment of lower levels of H3K4me3 to the Rhbdf1 promoter, whereas loss of HS-39 had no detectable effect on local deposition of H3K4me3 ( Supplementary Fig. 5 ). Changes in H3K4me3 in the D3839 mutant are accompanied by higher levels of RNA polymerase II (Pol II) recruitment and increased chromatin accessibility (ATAC-seq) at the gene promoters. Surprisingly, we could not detect a decrease in the levels of H3K27me3 at the Rhbdf1 gene promoter despite its strong transcriptional activation (Fig. 6a,c,d ). To exclude the possibility that H3K27me3 was retained despite the loss of PRC2 recruitment following α-globin enhancer activation, we verified that binding of the PRC2 complex component Ezh2 is retained in the D3839 mutant (Fig. 6a,d) . Thus, it appears that insulation of the Rhbdf1 promoter from the α-globin enhancers by CTCF-cohesin is required for effective Polycomb-mediated transcriptional repression. This is not consistent with a model of simple chromatin encroachment. 
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Discussion
The above results indicate that following activation of the α-globin enhancers, selective convergent CTCF-cohesin-binding sites act as boundary elements and create an erythroid-specific chromatin structure, delimiting enhancer interactions and consequently ensuring an erythroid-specific transcriptional program (Fig. 6e) . The ability of active enhancers to interact with an unexpectedly wide range of receptive promoters was revealed when critical CTCF-cohesin elements were removed. More widespread and bidirectional enhancer interactions appeared and were associated with the upregulation of three genes; in one case (Rhbdf1) overcoming Polycomb-mediated repression. While genetic perturbation of CTCF binding has been shown to result in misregulation of gene expression in various cell lines and cancer [9] [10] [11] 28 , our more detailed investigation involving precise CTCF-site disruptions, and high-resolution chromatin conformation analysis (Capture-C) clearly link gene activation and acquisition of H3K4me3 to the establishment of aberrant enhancer contacts within a perturbed, tissue-specific sub-TAD. Importantly, we have shown that not all CTCF-cohesin sites subserve the same functions in the sub-TAD: HS-38 acts as a strong boundary element, HS-39 as a weaker element and HS-29 has no apparent insulator activity. The molecular basis of this is currently unknown.
In addition, we show that interactions between the two flanking clusters of CTCF sites are weaker or absent in ES cells despite the presence of CTCF and cohesin binding (Fig. 6e) . This raises the question of what regulatory mechanisms drive the tissue specificity of these CTCF interactions. As cohesin is loaded at active enhancerpromoter junctions 31 , one intriguing possibility is that additional cohesin recruitment in erythroid cells results in stabilization of flanking CTCF-CTCF interactions via a recently described loop extrusion mechanism 22, 32, 33 . In addition, the enhancer-promoter interactions that occur in erythroid cells may further stabilize the interactions between flanking CTCF binding sites.
In conclusion, our findings suggest that rather than enhancers having inherent specificity for their cognate promoters 34 , this communication is at least in part driven by the CTCF-mediated chromatin architecture that normally shields genes flanking a sub-TAD from the influence of enhancers in a tissue-specific manner 35, 36 . However, of interest, we have previously shown that the human α-globin enhancers may influence the expression of a gene (NME4) lying 400 kb away and outside of the orthologous region described here 37 . Therefore, insulation may not be absolute. Nevertheless, given the dynamic genome partitioning through development and differentiation described here, it seems likely that in addition to variants in enhancers and promoters, intergenic variants within critical CTCF-cohesin-binding sites will underlie changes in gene expression associated with a wide variety of complex traits and diseases.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. Isolation and selection of ter119 + cells from mice. Mature primary erythroid cells were obtained from young adult mice of both genders between 2 and 6 months of age that were pre-treated with acetylphenylhydrazine (APH) as described previously 45 . Spleens of APH-treated mice were mechanically disrupted to single-cell suspension in RPMI media (Thermo Fischer Scientific) supplemented with 10% fetal bovine serum (FBS, Gibco). To isolate late-stage erythroid cells, cells from a single spleen were resuspended in 5 ml of cold PBS/2% BSA and stained with 120 µl PE antiter119 antibody (Ly-76, BD Biosciences) at 4 • C for 15 min (ref. 46). After washing stained cells in PBS/0.5% BSA, cells were resuspended in 1.6 ml of PBS/0.5% BSA and 400 µl of anti-PE magnetic beads (Miltenyi Biotec) and incubated for 20 min at 4 • C. Ter119-positive cells were isolated via auto-magnetic-activated cell sorting (autoMACS, Miltenyi Biotec) and processed for downstream applications. Purity of the isolated erythroid cells was routinely verified by FACS.
Cell lines. The embryonic stem cell line ES-E14TG2a was used for gene expression
and Capture-C analysis and cultured according to standard conditions (ATCC CRL-1821). The E14TG2a line was a gift from A. Smith and was tested negative for mycoplasma and has been extensively authenticated by blastocyst injection. This cell line is not found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample.
Preparation of TALEN expression constructs.
For TALEN construction, a 500 bp sequence centred around the HS-38 CTCF consensus sequence was submitted to the TALE-NT Targeter using NN for G recognition (Golden Gate TALEN and TAL Effector Kit 1.0, Addgene) 26 . Two TALEN pairs with a differential spacer region that targeted the HS-38 CTCF binding sequence were selected and constructed via the Golden Gate assembly method 26 . TALEN-AF targeted the sequence 5 -TCC TGGGTAGGCCTCT-3 with the RVD array HD-HD-NG-NN-NN-NN-NG-NI-NN-NN-HD-HD-NG-HD-NG and TALEN-AR targeted the sequence 5 -GAGTC CCACGTATCGT-3 on the reverse strand with the RVD array NN-HD-NG-NI-NG-NN-HD-NI-HD-HD-HD-NG-NN-NI-NN. The vector RCIscript-Goldytalen (38142, Addgene) was used as the scaffold vector in the final step of the Golden Gate cloning protocol.
Preparation of CRISPR-Cas9 expression construct.
To generate the single guide-RNAs (sgRNAs) used to target CTCF binding sequences, oligonucleotides corresponding to the target protospacers were cloned into pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene plasmid no. 42230, pX330) or pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10) (Addgene plasmid no. 42335, pX335) vectors as described previously 47 . pX330 and pX335 were modified to contain a puromycin and neomycin selection cassette respectively. DNA oligonucleotides containing the 20 nt protospacer sequences are shown in Supplementary Table 1.
Preparation and injection of TALEN mRNA and CRISPR sgRNA. TALEN microinjections were performed as previously described 48 . DNA templates for use in in vitro transcription reactions were generated from CRISPR-Cas9 expression constructs by PCR. The forward, sgRNA-specific primer was modified with a 5 extension that contained a T7 polymerase binding site, and used to amplify the gRNA with a reverse primer binding downstream of the mature gRNA sequence (gRNA-R) (see Supplementary Table 1 ). The MEGAshortscript T7 Transcription Kit (Thermo Scientific) was used for in vitro transcription of the gRNAs. In vitro transcribed RNAs were purified with the MEGAclear Kit (Thermo Scientific) and diluted in 10 mM Tris-HCl pH 7.5, 0.1 mM EDTA pH 8.0 before microinjection. Manipulations using wild-type Cas9 were performed using a Cas9-expressing mouse line to provide a maternal supply of Cas9 to zygotes as previously described 49 . Briefly, female mice homozygous or heterozygous for the CAG-Cas9 transgene insertion were superovulated and mated with C57BL/6 or, for the production of double (D3839) mutants, with DEL38 studs. Oocytes were prepared for microinjection from plugged females and 20 ng µl −1 of gRNA was injected into the pronucleus. Depending on the experiment, ssODN templates for HDR (Eurogentec) were added at a final concentration of 20 ng µl −1 (see Supplementary  Table 1 ). For the single mutation of HS-39, D10A Cas9 protein (PNA Bio) was injected with two sgRNAs at a concentration of 40 ng µl −1 into C57BL/6 oocytes. The microinjected zygotes were immediately transferred to pseudopregnant CD1 foster mothers.
Next-generation Capture-C. Next-generation Capture-C was performed as previously described 17 . A total of 2 × 10 7 mouse ES cells or isolated ter119 + mouse spleen cells were used per biological replicate experiment and processed in parallel. To visualize differences in Capture-C profiles, normalized interactions in ES cells or erythroid cells of CTCF binding site mutants were subtracted from wild-type erythroid interactions to generate a differential Capture-C track. For plotting of multiple interaction profiles simultaneously, Capture-C interactions were binned in 250 bp bins and a sliding 5 kb window was used. The mean of three biological replicates and standard deviation were plotted in R.
ATAC-sequencing. ATAC-seq was performed on 65,000 ter119+ cells isolated from APH-treated mouse spleens and mouse ES cells as previously described 50 . Data was mapped to the genome using an in-house analysis pipeline as previously described 15 .
RNA expression analysis. Isolation of total RNA was performed by lysing 1 × 10 7 mouse ES or purified ter119+ cells in TRI reagent (Sigma) according to the manufacturer's instructions. To remove genomic DNA from RNA samples, samples were treated with TURBO DNase with the DNA-free DNA removal kit (Ambion). DNase-treated RNA samples were stored at −80 • C. To assess relative changes in gene expression by qPCR, 1 µg of total RNA was used for cDNA synthesis using the Superscript III first-strand synthesis SuperMix (Invitrogen). The C t method was used for relative quantitation of RNA abundance using the primers in Supplementary Table 1 . For RNA-seq libraries, rRNA and globin mRNA species were removed using the Globin-Zero Gold kit (Illumina) with 5 µg of total RNA according to the manufacturer's instructions. To further enrich for mRNA, poly(A)+ mRNA was isolated using the NEBNext Poly(A) mRNA magnetic isolation module (New England Biolabs) followed by a NEBNext Ultra directional RNA library preparation (New England Biolabs) according to the manufacturer's instructions. Fragmentation of mRNA was achieved by incubating samples at 95 • C for 12 min. To achieve strand specificity, actinomycin D was added (5 µl of 0.1 µg µl −1 ) to the first-strand cDNA synthesis reaction. Poly(A)+ libraries (4 nM) were sequenced on the Illumina NextSeq platform. All RNA-seq data sets were aligned to the mm9 mouse genome build using STAR 51 . Deeptools bamCoverage was used to calculate normalized (RPKM) and strand-specific read coverage, which was visualized in the UCSC genome browser. Mapped RNA-seq reads were assigned to genes using Subread featureCounts using RefSeq gene annotation. Normalized differential gene expression, between biological triplicate data from littermate wild-type and CTCF binding site mutant mice extracted in parallel, was calculated with the DESeq2 R package.
De novo CTCF motif analysis in ter119 + cells. Motif analysis was performed as previously described 52 . Briefly, 2,000 CTCF peak sequences from ter119 + cells were retrieved and used for de novo motif discovery using the MEME suite. The motif with the highest score matched the previously published consensus CTCF core binding motif. Significant matches (P < 10 −3 ) for the CTCF core motif within all CTCF peak regions were identified using FIMO. When multiple core motifs were detected within the same peak region, only the best match was retained. Motifs up-and downstream of the core motif were identified from 6,000 randomly selected 20 bp sequences of up-and downstream flanks and were similar to those previously identified 52 . Analysis of spacing between the core and flanking motifs revealed a preferential spacing for both up-and downstream motifs. Significant upstream or downstream motif matches (P-value threshold of 10 −2 ) were added to CTCF peak annotation only if the motifs were present at the preferred spacing (5-6 bp for upstream motif, 4-6 for downstream motif).
DNaseI footprint analysis. DNaseI footprints and meta-plots at CTCF binding sites were generated using a custom perl script based on Samtools using previously published C57BL/6 DNaseI-seq data 41 . DNaseI-seq cuts were counted as the 5 end of the first read and the 3 end of the second read of DNA fragments. For metaplots of CTCF peaks with different combinations of core and auxiliary motifs, average cut-counts relative to the start of the CTCF core sequence were calculated for each category.
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Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) was performed on purified ter119-positive primary erythroid cells (1 × 10 7 cells per ChIP) using the ChIP Assay Kit (Cat. No. 17-295, Millipore). For ChIP of cohesin component Rad21, cells were subjected to dual crosslinking with 2 mM disuccinimidyl glutarate (DSG, Thermo Fischer Scientific) for 50 min and 1% (v/v) formaldehyde for 10 min, whereas a single 10 min 1% formaldehyde fixation was used for all other antibodies (see details in the Reporting Summary). Chromatin fragmentation was performed with the Bioruptor sonicator (Diagenode) for 15 min at 4 • C to obtain an average fragment size between 200 and 500 bp. Immunoprecipitated DNA fragments were analysed by qPCR or sequencing. Primers used for qPCR are listed in Supplementary Table 1 . DNA libraries for sequencing were prepared with the NEBNext Ultra II DNA library prep kit (New England Biolabs) and sequenced on the Illumina platform.
Analysis of ChIP-seq data. ChIP-seq data was mapped to the genome using an in-house analysis pipeline as previously described 15 . The MACS (Model-based analysis of ChIP-seq) peak finding algorithm was used to identify regions of ChIP-seq enrichment over background in an unbiased manner. The MACS2 callpeak function was used on biological duplicate ChIP-seq data of CTCF (-q 10 −5 ) and H3K4me3 (-q 10 −3 ). For H3K27me3, the MACS2 callpeak function was used with the-broad-cutoff option (-broad-cutoff 0.05) on biological duplicate ChIP-seq data. To identify regions that were differentially enriched between wild-type and CTCF binding site mutant mice, the R package DiffBind was used. Two biological duplicate data sets and independent peak calls of CTCF, H3K4me3 and H3K27me3 were used to identify differentially enriched regions with a false discovery rate (FDR) of 0.05. Differential analysis within the DiffBind package was performed with DESeq2.
Statistics and reproducibility. Statistical analysis was carried out with Graphpad
Prism (version 7.0c) unless otherwise indicated. All gene expression experiments (both RT-qPCR and RNA-seq) were performed on three biological replicates with similar results (standard deviation (s.d.) is shown for all measurements). Statistical analysis was performed using multiple unpaired, two-tailed t-tests and corrected for multiple comparisons using the Holm-Sidak method where appropriate. The statistical analysis of RNA-seq data was performed in R using the Bioconductor DEseq2 package. All Capture-C experiments were performed on three biological replicates with similar results. The standard deviation of 250 bp bins was calculated in R and visualized to illustrate the reproducibility of this chromatin interaction analysis. All ChIP experiments newly generated for this study were performed at least in biological duplicate with similar results. The analysis of ChIP-seq data was performed with Bioconductor package DiffBind, using DEseq2 to determine false discovery rate (FDR). P values are represented as * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001.
Data availability. RNA-sequencing, ChIP-sequencing, ATAC-sequencing and Capture-C data generated for this study have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE97871. Previously published ChIPseq data that were reanalysed here are available under the following accession codes: GSE27921, GSE31039, GSE30203. Previously published Capture-C data that were reanalysed here are available under the accession code GSE67959. Previously published DNaseI-and ATAC-seq data that were reanalysed here are available under the accession codes GSE49460 and GSE94249. All other data supporting the findings of this study are available from the corresponding author on reasonable request. Mean RNA abundance is plotted on the x-axis and enrichment is plotted on the y-axis. No significant changes in local gene expression were detected as shown on the plot by the genes highlighted in blue: Snrnp25, Rhbdf1, Mpg. Controls are shown in different colours: Mitoferrin-1 (Slc25a37, green), a highly expressed erythroid gene; Sh3pxd2b and Il9r (red), repressed in erythroid; Nprl3 (yellow), a housekeeping gene within the α-globin locus that is unaffected by HS-29 deletion. The five most significant outliers were investigated and only one gene was located in cis to α-globin (Irgm2, >25Mb removed), making it unlikely that these expression changes represent direct effects from HS-29 deletion.
Significance was tested with a Wald test (DEseq2, n=3 independent experiments in which 3 animals were analysed). B. Normalised ATACSeq and ChIP-seq read-densities (RPKM; 2 independent experiments in which 2 animals were analysed in total) for H3K27me3, H3K4me3, and CTCF at the α-globin locus both in WT and D29 primary erythroid cells. 
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The following antibodies were used in this study for ChIP. Prior to use in ChIP-seq in C57BL/6 mouse erythroid cells, these antibodies were validated for enrichment at known positive sites by ChIP-qPCR. All of the antibodies have previously been used and published in ChIP-seq studies. No commonly misidentified cell lines were used Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
C57BL/6J mice were sourced from MRC Harwell/Charles River Laboratories. Young adult mice of both genders between 2 and 6 months of age were used in experiments. Mice were pre-treated with acetylphenylhydrazine (APH) after which mice were sacrificed and erythroid cells (ter119+) were isolated from the removed spleen.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants
